The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy
Open accessAbstract
Antibody-drug conjugates (ADCs) are a class of highly potent biopharmaceutical drugs generated by conjugating cytotoxic drugs with specific monoclonal antibodies through appropriate linkers. Specific antibodies used to guide potent warheads to tumor tissues can effectively reduce undesired side effects of the cytotoxic drugs. An in-depth understanding of antibodies, linkers, conjugation strategies, cytotoxic drugs, and their molecular targets has led to the successful development of several approved ADCs. These ADCs are powerful therapeutics for cancer treatment, enabling wider therapeutic windows, improved pharmacokinetic/pharmacodynamic properties, and enhanced efficacy. Since tubulin inhibitors are one of the most successful cytotoxic drugs in the ADC armamentarium, this review focuses on the progress in tubulin inhibitor-based ADCs, as well as lessons learned from the unsuccessful ADCs containing tubulin inhibitors. This review should be helpful to facilitate future development of new generations of tubulin inhibitor-based ADCs for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Overview of the immune response
Chaplin, D. D. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.12.980 · Cited by 2,235
Tracking the ends: a dynamic protein network controls the fate of microtubule tips
Akhmanova, A., & Steinmetz, M. O. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2369 · Cited by 1,047
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
Chari, R. V. J., Miller, M. L., & Widdison, W. C. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307628 · Cited by 930
Rudnick, S. I., Lou, J., Shaller, C. C., Tang, Y., Klein-Szanto, A. J. P., Weiner, L. M., Marks, J. D., & Adams, G. P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2277 · Cited by 365
Trimurtulu, G., Ohtani, I., Patterson, G. M. L., Moore, R. E., Corbett, T. H., Valeriote, F. A., & Demchik, L. (1994) · Journal of the American Chemical Society · doi:10.1021/ja00090a020 · Cited by 303
Erickson, H. K., Widdison, W. C., Mayo, M. F., Whiteman, K., Audette, C., Wilhelm, S. D., & Singh, R. (2010) · Bioconjugate Chemistry · doi:10.1021/bc900315y · Cited by 246
Golakoti, T., Ogino, J., Heltzel, C. E., Le Husebo, T., Jensen, C. M., Larsen, L. K., Patterson, G. M. L., Moore, R. E., Mooberry, S. L., Corbett, T. H., et al. (1995) · Journal of the American Chemical Society · doi:10.1021/ja00154a002 · Cited by 186
Clinical status of anti-cancer agents derived from marine sources
Singh, R., Sharma, M., Joshi, P., & Rawat, D. (2008) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152008785133074 · Cited by 143
Cited by
Antibody-Drug Conjugate-Based Therapeutics: State of the Science
Birrer, M. J., Moore, K. N., Betella, I., & Bates, R. C. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz035 · Cited by 439
Antibody–Drug Conjugates for Cancer Therapy
Hafeez, U., Parakh, S., Gan, H. K., & Scott, A. M. (2020) · Molecules · doi:10.3390/molecules25204764 · Cited by 395
Coats, S., Williams, M., Kebble, B., Dixit, R., Tseng, L., Yao, N.-S., Tice, D. A., & Soria, J.-C. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0272 · Cited by 289
Antibody–drug conjugates: Recent advances in payloads
Wang, Z., Li, H., Gou, L., Li, W., & Wang, Y. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.06.015 · Cited by 264
Self-citationDragovich, P. S., Pillow, T. H., Blake, R. A., Sadowsky, J. D., Adaligil, E., Adhikari, P., Bhakta, S., Blaquiere, N., Chen, J., dela Cruz-Chuh, J., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01845 · Cited by 152
Metadata
- Authors
- Chen, H., Lin, Z., Arnst, K., Miller, D., & Li, W.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2017-08-01
- Volume
- 22
- Issue
- 8
- Pages
- 1281
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W2740434250
- Cited by
- 214
- References
- 10
- FWCI
- 12.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy. https://app.cochat.ai/papers/10.3390/molecules22081281
- The paper
- Chen, H., Lin, Z., Arnst, K., Miller, D., & Li, W. (2017). Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy. Molecules. https://doi.org/10.3390/molecules22081281
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.